Truist maintains Buy on IOVA stock with a $25 target
Truist Securities confirmed its positive stance on Iovance Biotherapeutics (NASDAQ:IOVA) shares, maintaining a Buy rating and a price target of $25.00. With the stock currently trading at $6.07, this ...
What's Wrong With Iovance Biotherapeutics Stock?
It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...
Truist Financial Releases a Buy Rating on Iovance Biotherapeutics (IOVA)
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research ...
Where Will Iovance Biotherapeutics Be in 5 Years?
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...
Stifel maintains Buy on Iovance stock with $21 target
Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to InvestingPro data, the stock currently trades at $6.40, with analyst ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA) and Madrigal Pharmaceuticals (MDGL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and ...
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the ...
Peninsula biotech company sues insurance company to cover patients' injuries in clinical trials
A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...